TABLE 1.
Participating laboratory sites (deidentified) and their corresponding assay methodologies used for testing of the U.S. serology standard
| Site | Manufacturer | Assay | Antigen | Conjugate isotype |
|---|---|---|---|---|
| 1 | Abbott | AdviseDX SARS-CoV-2 | Spike | IgM |
| 1 | Abbott | Affinity I SARS-CoV-2 | Nucleocapsid | IgG |
| 1 | In-house | Anti-SARS-CoV-2 | Spike | IgG |
| 1 | In-house | Anti-SARS-CoV-2 orthogonal assay | RBD, then Spike | IgG |
| 1 | In-housea | Anti-SARS-CoV-2 orthogonal assay | RBD, then Spike | IgG |
| 2 | In-house | Anti-SARS-CoV-2 | Spike | IgG |
| 2 | In-house | Anti-SARS-CoV-2 | Spike | IgM |
| 3 | Roche | Elecys anti-SARS-CoV-2 | Nucleocapsid | Total |
| 4 | Euroimmun | Anti-SARS-CoV-2 | Spike S1 | IgG |
| 4 | Abbott | Architect SARS-CoV-2 | Nucleocapsid | IgG |
| 5 | In-house | Fluorescence reduction neutralization assay | Wild-type virus | Total |
| 6 | In-house | Anti-SARS-CoV-2 | Spike | IgG |
| 6 | In-house | RBD-ACE2-PE | RBD-ACE2 | Total |
| 7 | In-house | Anti-SARS-CoV-2 | Spike | IgG |
| 7 | In-house | Anti-SARS-CoV-2 | Spike | IgM |
| 7 | In-house | Anti-SARS-CoV-2 | Nucleocapsid | IgG |
| 7 | In-house | Anti-SARS-CoV-2 | Nucleocapsid | IgM |
| 8 | MSD | Anti-SARS-CoV-2 multiplex assay | RBD/Spike/Nucleocapsid | IgG |
a
As assay developed for commercial use.